ArticleRadiation oncology (London, England)2019
Effects of the Bragg peak degradation due to lung tissue in proton therapy of lung cancer patients.
Article in Radiation oncology (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness and safety of proton therapy in intracranial meningioma treatment: a systematic review and meta-analysis.Neurosurgical review · 2026Pooled it
- On the Way to Accounting for Lung Modulation Effects in Particle Therapy of Lung Cancer Patients-A Review.Cancers · 2024Review
- Spectrum of Imaging Patterns of Lung Cancer following Radiation Therapy.Diagnostics (Basel, Switzerland) · 2023Review
- Gold-Nanoparticles-Enhanced Production of Reactive Oxygen Species in Cells at Spread-Out Bragg Peak under Proton Beam Radiation.ACS omega · 2023Article
- Proton Beam Therapy versus Photon Radiotherapy for Stage I Non-Small Cell Lung Cancer.Cancers · 2022Article
- Anthropomorphic lung phantom based validation of in-room proton therapy 4D-CBCT image correction for dose calculation.Zeitschrift fur medizinische Physik · 2022Article
- Dosimetric impact of tumor position displacements between photon and proton stereotactic body radiation therapy for lung cancer.Journal of radiosurgery and SBRT · 2022Article
- Correction to: Effects of the Bragg peak degradation due to lung tissue in proton therapy of lung cancer patients.Radiation oncology (London, England) · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo quantify the effects of the Bragg peak degradation due to lung tissue on treatment plans of lung cancer patients with spot scanning proton therapy and to give a conservative approximation of these effects. METHODS AND MATERIALS: Treatment plans of five lung cancer patients (tumors of sizes 2.7-46.4 cm
resultsThe Bragg peak degradation leads to a lower dose in the CTV and higher doses in OARs distal to the CTV compared to the prediction from the TPS. The reduction of the mean dose in the CTV was - 5% at maximum and - 2% on average. The deeper a tumor was located in the lung and the smaller its volume the bigger was the effect on the CTV. The enhancement of the mean dose in OARs distal to the CTV was negligible for the cases investigated.
conclusionsEffects of the Bragg peak degradation due to lung tissue were investigated for lung cancer treatment plans in proton therapy. This study confirms that these effects are clinically tolerable to a certain degree in the current clinical context considering the various more critical dose uncertainties due to motion and range uncertainties in proton therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.